dacarbazine + bortezomib

Dacarbazine + bortezomib is an investigational combination of two small molecule anticancer agents. Dacarbazine is an alkylating agent that induces DNA damage through the formation of monofunctional alkyl-DNA adducts, leading to cell death. Bortezomib is a proteasome inhibitor that blocks the 26S proteasome, resulting in disruption of protein degradation, cell cycle arrest, and apoptosis in cancer cells. Preclinical studies suggest that bortezomib can enhance the cytotoxic activity of dacarbazine. This combination has been evaluated in phase I clinical trials for melanoma and soft tissue sarcoma, where it demonstrated tolerability and some antitumor activity[1][2].